At Janssen Biotech, Inc., (click here) we dedicate our hearts and minds to improving the health of individuals living with serious conditions.
Mantle cell lymphoma (MCL) (click here) is a rare, B-cell NHL that most often affects men over the age of 60. The disease may be aggressive (fast growing) but it can also behave in a more indolent (slow growing) fashion in some patients. MCL comprises about five percent of all NHLs. The disease is called "mantle cell lymphoma" because the tumor cells originally come from the "mantle zone" of the lymph node. MCL is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone marrow.
Not since zidovudine/Retrovir/AZT has the FDA approved a drug so swiftly. The USA is finding wonder drugs and they have every reason to be proud of these accomplishments.
Single-agent oral therapy (click here) is one of the first medications to be approved via the U.S. Food and Drug Administration's Breakthrough Therapy Designation Pathway
Janssen Biotech, Inc. ["Janssen"] (click here) today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established....
Press Release (click here)
Janssen is a subsidiary of Johnson and Johnson. It is a incredible break through for older men that are diagnosed with a nearly undetectable and rapid growing cancer. This gives great hope to those Americans and others around the world.
The FDA worked quickly to release this drug for current sufferers. They did a great job with Fast Track.
Mantle cell lymphoma (MCL) (click here) is a rare, B-cell NHL that most often affects men over the age of 60. The disease may be aggressive (fast growing) but it can also behave in a more indolent (slow growing) fashion in some patients. MCL comprises about five percent of all NHLs. The disease is called "mantle cell lymphoma" because the tumor cells originally come from the "mantle zone" of the lymph node. MCL is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone marrow.
Not since zidovudine/Retrovir/AZT has the FDA approved a drug so swiftly. The USA is finding wonder drugs and they have every reason to be proud of these accomplishments.
Single-agent oral therapy (click here) is one of the first medications to be approved via the U.S. Food and Drug Administration's Breakthrough Therapy Designation Pathway
PR Newswire
HORSHAM, Pa., Nov. 13, 2013
HORSHAM, Pa., Nov. 13, 2013
/PRNewswireJanssen Biotech, Inc. ["Janssen"] (click here) today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.1 This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established....
Press Release (click here)
Janssen is a subsidiary of Johnson and Johnson. It is a incredible break through for older men that are diagnosed with a nearly undetectable and rapid growing cancer. This gives great hope to those Americans and others around the world.
The FDA worked quickly to release this drug for current sufferers. They did a great job with Fast Track.
